María Victoria
Mateos Manteca
Profesora Titular de Universidad
![Foto de María Victoria](/img/nophoto.png)
![Foto de Instituto de Salud Carlos III](/img/noimage_org.png)
Instituto de Salud Carlos III
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Instituto de Salud Carlos III (12)
2024
-
Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma
Clinical Cancer Research
2023
2022
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
2021
-
B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients
Cancers, Vol. 13, Núm. 7
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
-
Immune system alterations in multiple myeloma: Molecular mechanisms and therapeutic strategies to reverse immunosuppression
Cancers, Vol. 13, Núm. 6, pp. 1-26
-
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma
Cancers, Vol. 13, Núm. 19
2020
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
-
Protein translation inhibition is involved in the activity of the pan-pim kinase inhibitor pim447 in combination with pomalidomide-dexamethasone in multiple myeloma
Cancers, Vol. 12, Núm. 10, pp. 1-20
2018
-
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
Blood cancer journal, Vol. 8, Núm. 12, pp. 117